Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 3Advanced Malignant Solid Tumors 3Carcinoma, Non-Small-Cell Lung 2Thymoma 1Stomach Neoplasms 1Renal Cell Cancer Metastatic 1Kidney Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1Advanced Cancer 1

Interventions

Nivolumab 20Ipilimumab 10Surveys and Questionnaires 7Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Interviews as Topic 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancer × vorolanib × Clear all
NCT01863485 2019-07-05

Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China

AnewPharma

Phase 1 Completed
44 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡